Why carry out this study?
|
Guselkumab has demonstrated efficacy in moderate-to-severe psoriasis and across multiple domains of psoriatic arthritis (PsA), including skin and joint manifestations. Among patients with moderate-to-severe psoriasis, those treated with guselkumab have achieved significantly greater improvements in psoriasis involving difficult-to-treat body regions (nails, scalp, palms and/or soles). |
Nail disease is a common manifestation of PsA and is associated with more active disease overall (including more swollen/tender joints, more severe skin disease, and increased pain and fatigue). |
This post hoc analysis was performed to evaluate the efficacy of guselkumab in treating psoriasis of the nails, scalp, palms and/or soles in patients with PsA. |
What were the study outcomes/conclusions?
|
In the subset of patients with moderate-to-severe disease and self-reported PsA diagnosis, guselkumab demonstrated meaningful improvements in psoriasis involving the nails, scalp, palms, and/or soles at week 16 of treatment compared with placebo, lessening the impact of psoriasis on health-related quality of life (HRQoL). Greater mean improvements in psoriasis of the nails, scalp, and palms and/or soles were observed with guselkumab through week 24 compared with adalimumab, and response rates were consistent at 1 year. |
Guselkumab offers an effective treatment option with durable therapeutic benefits for patients with moderate-to-severe psoriasis and with psoriasis involving the nails, scalp, palms and/or soles, including patients with coexistent PsA. Improvement in psoriasis of these difficult-to-treat body regions is associated with better HRQoL. These findings should be considered when selecting a treatment for regional forms of psoriasis, which commonly affect patients with PsA. |
Open Access 15.09.2023 | Brief Report
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
Erschienen in: Dermatology and Therapy | Ausgabe 11/2023